Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022;17(3):183-189.
doi: 10.5114/pg.2021.111401. Epub 2021 Dec 8.

Vonoprazan in the management of erosive oesophagitis and peptic ulcer-induced medication: a systematic review

Décio Chinzon  1 , Joaquim Prado P Moraes-Filho  1 , Gerson Domingues  2 , Juliana Leite Soares Guedes  3 , Cláudia Yang Santos  3 , Schlioma Zaterka  1
Affiliations
Review

Vonoprazan in the management of erosive oesophagitis and peptic ulcer-induced medication: a systematic review

Décio Chinzon et al. Prz Gastroenterol. 2022.

Abstract

Introduction: Vonoprazan has been found to promote a better antisecretory effect addressing acid-related diseases' unmet needs.

Aim: To assess if vonoprazan effectively treats patients diagnosed with gastroesophageal reflux disease esophagitis or with peptic ulcers induced by chronic use of aspirin or non-steroidal anti-inflammatory drugs.

Material and methods: A literature search was conducted (April/2021) using Medline via PubMed, Cochrane library, Lilacs, Scielo, and Centre for Reviews and Dissemination electronic databases.

Results: We retrieved 55 titles. Of these, 13 met the eligibility criteria and were included in this review. Of these 13 articles, 4 were prospective cohort studies, 1 was a follow-up analysis of a preceding prospective study, 1 was a retrospective cohort study, and 6 were randomized clinical trials.

Conclusions: Our findings suggest that vonoprazan was effective and non-inferior to proton pump inhibitors in healing and maintaining healed reflux oesophagitis, leading to faster symptom relief. Vonoprazan may also be considered for preventing aspirin- or non-steroidal anti-inflammatory drug-related peptic ulcer recurrence.

Keywords: gastroesophageal reflux disease; oesophagitis; proton pump inhibitors; systematic review; ulcer.

PubMed Disclaimer

Conflict of interest statement

DC has received fees as advisory board member for Takeda. JPPMF and GD has received fees as speaker for Takeda. JLSG and CYS are Takeda Pharmaceuticals Brazil full-time employees. Takeda Pharmaceuticals Brazil funded this work.

Figures

Figure 1
Figure 1
Study flow chart
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. He HS, Li BY, Chen QT, et al. . Comparison of the use of vonoprazan and proton pump inhibitors for the treatment of peptic ulcers resulting from endoscopic submucosal dissection: a systematic review and meta-analysis. Med Sci Monit 2019; 25: 1169-76. - PMC - PubMed
    1. Hoshino S, Kawami N, Takenouchi N, et al. . Efficacy of vonoprazan for proton pump inhibitor-resistant reflux esophagitis. Digestion 2017; 95: 156-61. - PubMed
    1. Ochiai Y, Iizuka T, Hoshihara Y, et al. . Efficacy of vonoprazan for refractory reflux esophagitis after esophagectomy. Dig Dis 2021; 39: 569-76. - PMC - PubMed
    1. Mori H, Suzuki H. Role of acid suppression in acid-related diseases: proton pump inhibitor and potassium-competitive acid blocker. J Neurogastroenterol Motil 2019; 25: 6-14. - PMC - PubMed
    1. Hunt RH, Scarpignato C. Potassium-competitive acid blockers (P-CABs): are they finally ready for prime time in acid-related disease? Clin Transl Gastroenterol 2015; 6: e119-4. - PMC - PubMed